MGD-22

MGD-22 (0-100 μM, 96 h) exhibits extremely potent anti-proliferative activity against multiple myeloma (MM) cell lines including NCI-H929 (IC₅₀ = 7.93 nM), RPMI-8226 (IC₅₀ = 83.2 nM), OPM-2 (IC₅₀ = 7.87 nM); acute myeloid leukemia (AML) cell lines including MV-4-11 (IC₅₀ = 5.38±0.43 nM), U937 (IC₅₀ = 15.1 nM), MOLM-13 (IC₅₀ = 196 nM), KG-1 (IC₅₀ = 78.9 nM), Skm-1 (IC₅₀ = 218 nM), MUTZ-1 (IC₅₀ = 148 nM); diffuse large B-cell lymphoma (DLBCL) cell lines including WSU-DLCL-2 (IC₅₀ = 8.99 nM), Ocl-Ly3 (IC₅₀ = 95.3 nM), SU-DHL-4 (IC₅₀ = 452 nM), TMD8 (IC₅₀ = 87.7 nM), U2932 (IC₅₀ = 8.17 nM); while showing negligible activity against normal peripheral blood mononuclear cells (PBMCs) and primary B cells (IC₅₀ > 33 μM^[1].
MGD-22 (0.01-10 μM, 72 h) induces dose-dependent apoptosis in NCI-H929 and MV-4-11 cells^[1].
MGD-22 (0.001-1000 nM, 24 h) selectively induces robust degradation of IKZF1/2/3 in HEK293T cells engineered with IKZF1/2/3-HiBit tags, with DC₅₀ values of 8.33 nM (IKZF1), 9.91 nM (IKZF2), and 5.74 nM (IKZF3), and maximal degradation (D_max) of 94.33%, 91.58%, and 92.26% respectively^[1].
MGD-22 (1 μM, 24 h) promotes the formation of a ternary complex between IKZF1/2/3 and CRBN in NCI-H929 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.